- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01894347
Prospective Observational Pilot-study for the Evaluation of the Nephro- an Neurotoxicity in the Anti-infectious Therapy With Inhalative Colistin Therapy for Patients With Ventilator-associated Pneumonia (VAP) (LOKALE)
Multi-Drug resistant pathogens (MDR) are reported worldwide with increasing incidence, especially in intensive care settings.
One of the drugs which are effective against MDRs, is colistin (polymyxin E). This agent has been reintroduced in response to the increase of MDR pathogens and might be used more often in the future. Data on safety regarding the most important side effects are not sufficiently available. l This study evaluates the toxicity in patients who receive aerosolized colistin.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
There is growing evidence that patients in the ICU setting have a special risk profile for consecutive colonization and possible infection due to MDR pathogens.
One therapy option is the use of inhalative colistin, as this agent has been demonstrated to be effective against these pathogens. Data on pharmacodynamics or - kinetics are transferred from older studies or from other patient populations. For patients with pulmonary colonization or infection due to an MDR pathogen the systemic resorption of the drug is not known, consequently systemic side effects including kidney or neural damage are not predictable.
This study focus on patients with inhalative colistin therapy and uses therapeutic drug monitoring to determine the rate of systemic resorption of colistin. For the evaluation of neurotoxicity function of peripheral nerves (neve conduction velocity) and of the eighth cranial nerve is monitored. Nephrotoxicity is estimated by creatinine level (-clearance) and the RIFLE criteria.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, 13353
- Charité Universitätsmedizin Charité
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion criteria:
- invasive ventilated patients (male and female) with assumed or assured bacteria with an elevated resistance pattern found in a tracheal or bronchial secretion with or without clinical signs of infection
- indicated colistin co-therapy or eradication-attempt with inhalative colistin (β-Lactam) therapy according to the standard operation procedure (SOP) of the hospital
Exclusion criteria:
- Consent of the patient or of the patient´s legal representative can´t be obtained soon
- Age < 18 years
- Included within another, prospective clinical antibiotics-study
- Hypersensitivity to colistin or polymyxin B
- Patients with cystic fibrosis
- Present letter of attorney or patient´s provision, which precludes a priori the participation in studies
- Missing consent for storage of pseudonymised data in context of the study
- The patient is in an institution due to a court injunction or administrative order
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Colistin inhalative
Adult ICU patients with
Patients included into the study group receive additional TDM, Monitoring of Neuro-and Nephropathology |
Therapeutic drug monitoring of serum levels and Monitoring of Neuro- and Nephropathology
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number and frequency of adverse events (nephro- or neurotoxicity after aerosolised colistin therapy)
Time Frame: 28 days
|
Adverse events are measured based on validated criteria:
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum concentration of colistin and β-Lactam antibiotics
Time Frame: 3 days
|
Colistin-concentration in serum following inhalative therapy (in mg/L) 2 hours and 8 hours of application and in steady state on day 3 of therapy
|
3 days
|
Serum levels of colistin and β-Lactam antibiotics (e.g. Meropenem)in mg/L
Time Frame: 3 days
|
Serum drug levels in mg/L 2hours, 8 hours and 3 days (steady state) after therapy induction
|
3 days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Maria Deja, Prof., Charité Universititaetsmedizin Berlin
Publications and helpful links
General Publications
- Falagas ME, Siempos II, Rafailidis PI, Korbila IP, Ioannidou E, Michalopoulos A. Inhaled colistin as monotherapy for multidrug-resistant gram (-) nosocomial pneumonia: a case series. Respir Med. 2009 May;103(5):707-13. doi: 10.1016/j.rmed.2008.11.018. Epub 2008 Dec 31.
- Falagas ME, Rafailidis PI. Nephrotoxicity of colistin: new insight into an old antibiotic. Clin Infect Dis. 2009 Jun 15;48(12):1729-31. doi: 10.1086/599226. No abstract available.
- Michalopoulos AS, Karatza DC. Multidrug-resistant Gram-negative infections: the use of colistin. Expert Rev Anti Infect Ther. 2010 Sep;8(9):1009-17. doi: 10.1586/eri.10.88.
- Hamer DH. Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin. Am J Respir Crit Care Med. 2000 Jul;162(1):328-30. doi: 10.1164/ajrccm.162.1.9910071.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Chemically-Induced Disorders
- Pathologic Processes
- Nervous System Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Lung Diseases
- Disease Attributes
- Cross Infection
- Iatrogenic Disease
- Poisoning
- Healthcare-Associated Pneumonia
- Pneumonia
- Neurotoxicity Syndromes
- Pneumonia, Ventilator-Associated
Other Study ID Numbers
- LOKALE
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infection Resistant to Multiple Drugs
-
Catholic University of the Sacred HeartUniversity Hospital, Geneva; Universiteit Antwerpen; Clinical Centre of Serbia; Canisius-Wilhelmina Hospital and other collaboratorsUnknownInfection Due to ESBL Bacteria | Bacterial Resistance | Infection Resistant to Multiple Drugs | Staph Aureus Methicillin Resistant ColonizationItaly, Romania, Serbia
-
Seattle Children's HospitalRecruitingInfection Resistant to DrugsUnited States
-
Hat Yai Medical Education CenterTerminatedPneumonia, Ventilator-Associated | Colistin Adverse Reaction | Infection Due to Multidrug Resistant Acinetobacter | Infection Resistant to Multiple DrugsThailand
-
Duke UniversityNational Institute of Allergy and Infectious Diseases (NIAID)CompletedBacterial Infections | Infections Resistant to Multiple DrugsChina, United States, Australia, Colombia
-
UMC UtrechtZonMw: The Netherlands Organisation for Health Research and DevelopmentCompletedInfection Resistant to Drugs | Gram-Negative Bacterial InfectionNetherlands
-
The University of The West IndiesRecruiting
-
Northwell HealthWithdrawnPlatelet Dysfunction Due to Drugs
-
The University of The West IndiesCompletedPlatelet Dysfunction Due to DrugsTrinidad and Tobago
-
The University of The West IndiesCompletedPlatelet Dysfunction Due to DrugsTrinidad and Tobago
-
University of MiamiWithdrawnInfection Due to Resistant Organism
Clinical Trials on TDM, Monitoring of Neuro-and Nephropathology
-
Assistance Publique Hopitaux De MarseilleNot yet recruitingPatients With Schizophrenia
-
National Institute of Allergy and Infectious Diseases...CompletedUsing Drug Levels in the Blood to Guide Therapy in HIV Infected Patients Taking a Protease InhibitorHIV InfectionsUnited States, Puerto Rico
-
Singapore General HospitalRecruitingSepsis | Bacterial Infections | Therapeutic Drug Monitoring | Hemodynamic Instability | Antimicrobial ResistanceSingapore
-
Inje UniversityMinistry of Science and ICTRecruitingLatent Tuberculosis | Tuberculosis | Nontuberculous Mycobacterium InfectionKorea, Republic of, Indonesia
-
Boston Medical CenterAmerican Society of Health-System PharmacistsRecruitingRheumatoid ArthritisUnited States
-
Hospital Italiano de Buenos AiresCompleted
-
University Hospital Schleswig-HolsteinRecruitingConversion DisorderGermany
-
Assistance Publique - Hôpitaux de ParisMinistry of Health, FranceCompletedHepatocellular CarcinomaFrance
-
Parc de Salut MarCompletedMultidrug Resistant Gram Negative Bacterial InfectionsSpain
-
Indiana UniversityWithdrawnRelapsed Germ Cell Cancer | Cisplatin Induced TinnitusUnited States